Purpose / DescriptionThis phase 3 single-arm open-label trial evaluated the safety and efficacy of 12 weeks of glecaprevir-pibrentasvir in 146 adults with compensated cirrhosis and genotype 1, 2, 4, 5, or 6 hepatitis C infection. Sixty percent were genotype 1 patients; 25% were treatment-experienced—most (69%) had previously received interferon-based treatment and the remainder had received sofosbuvir-based therapy. The overall sustained virologic response rate was 99%; one patient with genotype 1a experienced a viral relapse at week 8 post-treatment, and had Y93N substitution detected at baseline and at time of failure.